Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 6/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5968972 | 1.00 | KMT2A (0.46) | KMT2AMEN1SRRCA1CA2 | |
| SCHEMBL9776653 | 0.89 | KMT2A (0.45) | KMT2AMEN1CA1CA2MMP1 | |
| SCHEMBL7955761 | 0.82 | ALDH1A1 (0.48) | KMT2AMEN1CA1CA2MMP1 | |
| SCHEMBL7955717 | 0.82 | KMT2A (0.38) | KMT2AMEN1CA1CA2MMP1 | |
| SCHEMBL7955716 | 0.82 | ALDH1A1 (0.48) | KMT2AMEN1CA1CA2MMP1 | |
| SCHEMBL28690909 | 0.81 | KMT2A (0.47) | KMT2AMEN1SRRCA2CPA1 | |
| SCHEMBL5968987 | 0.81 | KMT2A (0.47) | KMT2AMEN1SRRCA2CPA1 | |
| SCHEMBL7067318 | 0.78 | AR (0.43) | KMT2AMEN1CA1CA2MMP1 | |
| SCHEMBL7066151 | 0.77 | KMT2A (0.40) | KMT2AMEN1CA1CA2MMP1 | |
| SCHEMBL9776597 | 0.76 | CYP1A2 (0.55) | KMT2AMEN1CYP19A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984627-B1 | Peptide derivatives | ASTRAZENECA AB (SE) | 2006-01-10 | — | — | US | disclosed |
| US-20050222395-A1 | New peptide derivatives | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | disclosed |
| EP-0799052-B1 | NEW ANTITHROMBOTIC FORMULATION, PROCESS FOR ITS MANUFACTURING, AND USE THEREOF | ASTRAZENECA AB (SE) | 2001-11-14 | — | — | EP | disclosed |
| EP-0701568-B1 | NEW PEPTIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-04-25 | — | — | EP | disclosed |
| EP-1067136-A1 | New peptide derivatives | AstraZeneca AB (SE) | 2001-01-10 | — | — | EP | disclosed |
| US-5939392-A | THROMBIN INHIBITORS, ANTICOAGULANTS AND ANTIINFLAMMATORY AGENTS | ASTRA AKTIEBOLAG (SE) | 1999-08-17 | — | — | US | disclosed |
| US-5856307-A | Peptide derivatives as kininogenase inhibitors | ASTRA AKTIEBOLAG (SE) | 1999-01-05 | — | — | US | disclosed |
| US-5795896-A | Antithrombotic formulation, process for its manufacturing, and use thereof | ASTRA AKTIEBOLAG (SE) | 1998-08-18 | — | — | US | disclosed |
| US-5783563-A | Method for treatment or prophylaxis of venous thrombosis | ASTRA AKTIEBOLAG | 1998-07-21 | — | — | US | disclosed |
| US-5780631-A | ANTICOAGLUANT | ASTRA AKTIEBOLAG (SE) | 1998-07-14 | — | — | US | disclosed |
| US-5723444-A | ENZYME INHIBITORS AND ANTICOAGULANTS | ASTRA AB (SE) | 1998-03-03 | — | — | US | disclosed |
| EP-0799052-A1 | NEW ANTITHROMBOTIC FORMULATION, PROCESS FOR ITS MANUFACTURING, AND USE THEREOF | Astra Aktiebolag (SE) | 1997-10-08 | — | — | EP | disclosed |
| US-5602253-A | STARTING MATERIAL FOR SERINE PROTEASE INHIBITORS | AKTIEBOLAGET ASTRA (SE) | 1997-02-11 | — | — | US | disclosed |
| WO-1996016671-A1 | NEW ANTITHROMBOTIC FORMULATION, PROCESS FOR ITS MANUFACTURING, AND USE THEREOF | ASTRA AKTIEBOLAG (SE) | 1996-06-06 | — | — | WO | disclosed |
| WO-1994029336-A1 | NEW PEPTIDE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222395-A1 | New peptide derivatives | SERPINE1, SERPINC1, SPINT2 | KMT2A 4410/4885MEN1 1137/4885SRR 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.